At Friends meeting, Pazdur, Woodcock lament FDA’s failure to protect the agency staff from political interference, warn of “lasting implications”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Richard Pazdur, former director of the FDA Oncology Center of Excellence, and Ellen Sigal, chairperson and founder of Friends of Cancer Research, at the Friends “Modernizing Oncology Endpoints: Pathways for Evidence and Policy” meeting Feb. 5.Credit: Friends of Cancer Research

For decades, FDA commissioners sought to insulate the agency’s professional staff from political interference with regulatory decisions.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Jacquelyn Cobb
Associate Editor
Table of Contents

YOU MAY BE INTERESTED IN

Jacquelyn Cobb
Associate Editor

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login